Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Determination of Protein Phosphorylation Helps Diagnose Blood Cancers

By LabMedica International staff writers
Posted on 21 Apr 2009
Determination of protein phosphorylation in blood or minute tissue specimens might replace biopsies for cancer diagnosis and response to treatment.

Scientists used a system capable of analyzing whether individual cancer-associated proteins were present in a drop of blood or minute tissue specimens and whether modifications of the proteins varied in response to cancer treatments. More...
The study focused on blood cancers, but the technique might also provide a faster, less invasive way to track solid tumors.

The Cell Biosciences (Palo Alto, CA, USA) protein analysis system used in the study is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which complicates protein analysis in limited samples. The Cell Biosciences system can measure cell-signaling proteins reproducibly in as few as 25 cells.

Stanford Medical School (Palo Alto, CA, USA) investigators collaborated with scientists from Cell Biosciences to separate cancer-associated proteins in narrow capillary tubes based on their charge, which varies according to modifications on the proteins' surface. Two versions of the same protein, one phosphorylated and one not, were easily distinguished because they traveled different distances in the tube. Antibodies were than used to identify the relative amounts and positions of the various proteins.

Variations in the way a protein is modified, or phosphorylated, can affect how it functions in tumor progression. Cancer cells often evade common therapies by altering their levels of protein expression and degrees of phosphorylation. Analyzing repeated small samples from a tumor undergoing treatment might allow doctors to head off rogue cells before they have a chance to proliferate into a more resistant tumor or to identify patients likely to fail standard approaches to treatment.

Alice Fan, M.D., a clinical instructor in the division of oncology at the Stanford medical school performed the study in the laboratory of Dean Felsher, MD, PhD, associate professor of medicine and of pathology and the leader of the Stanford molecular therapeutics program. "This technology allows us to analyze cancer-associated proteins on a very small scale," said Professor Felsher, a member of Stanford's Cancer Center, who studies how cancer genes called oncogenes initiate and influence tumor progression in many types of cancers. "Not only can we detect picogram levels--one-trillionth of a gram--of protein, but we can also see very subtle changes in the ways the protein is modified."

The study was reported in the advance online issue of the journal Nature Medicine on April 12, 2009.

Related Links:

Cell Biosciences
Stanford Medical School



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.